medicexum
Regulatory & Commercial ConsultancyUnited Kingdom

The compliance
advantage in cannabis.

Medicexum is the regulatory and commercial partner for suppliers, importers and clinics building inside the UK's most scrutinised emerging market.

Send an email enquiryExplore our services
Cannabis flower
CBMP · Schedule 2
EU GMP
Cannabis sativa L.
Trichome density 28%
UK Rx 2024+102%▲ YoY
Market 2028E£1.04B▲
MCR Patients60,000+
EU GMP partners12
Active clinics38
Compliance audits40+
Import routes9
Avg lead time14 days
UK Rx 2024+102%▲ YoY
Market 2028E£1.04B▲
MCR Patients60,000+
EU GMP partners12
Active clinics38
Compliance audits40+
Import routes9
Avg lead time14 days
UK Rx 2024+102%▲ YoY
Market 2028E£1.04B▲
MCR Patients60,000+
EU GMP partners12
Active clinics38
Compliance audits40+
Import routes9
Avg lead time14 days
01 — Market

The UK is the fastest-growing regulated cannabis market in Europe.

Demand is doubling. Regulation is tightening. Operators that treat compliance as competitive advantage will own the decade.

01CQC
0×
UK private prescriptions doubled in 2024
02Industry est.
£0.00B
Projected UK market value by 2028
03BMJ
0M
UK adults living with chronic pain
04YouGov
0%
Of UK adults open to medical cannabis
MHRA CompliantEU GMP SourcingHome Office LicensedGDP CertifiedResponsible PersonPatient-FirstWholesale DealerBritish PharmacopoeiaMHRA CompliantEU GMP SourcingHome Office LicensedGDP CertifiedResponsible PersonPatient-FirstWholesale DealerBritish PharmacopoeiaMHRA CompliantEU GMP SourcingHome Office LicensedGDP CertifiedResponsible PersonPatient-FirstWholesale DealerBritish Pharmacopoeia
02 — Services

A complete operating partner for cannabis-based medicinal products.

All services
01

Regulatory Compliance

MHRA, GDP and Home Office navigation. Audits, SOPs and Responsible Person frameworks.

02

Import & Export

EU GMP-compliant sourcing and licensed importation routes into the UK supply chain.

03

CBD & Novel Foods

FSA Novel Foods dossiers, public-list status, labelling and reformulation for UK CBD brands.

04

B2B Partnerships

Producers, importers and clinics matched into commercial relationships that scale.

05

Supply Chain Setup

License applications, storage, wholesale dealer obligations — stood up end-to-end.

06

Commercial Strategy

Pricing, positioning, go-to-market plans for new entrants and operators ready to scale.

03 — Position

Compliance is no longer a cost centre — it's the moat. The operators who treat MHRA, GDP and EU GMP as a strategic asset will define the UK market for the next decade.

Medicexum — Regulatory Perspective
Pharmaceutical lab
Live · MCR Registry
04 — Evidence

Evidence is rewriting the conversation.

UK Medical Cannabis Registry studies show meaningful improvements in anxiety, sleep and quality of life — including a 12-month ADHD cohort with adverse events under one in five.

0 mo
Cohort study window
0%
Adverse event rate
Read the study
05 — Engage

Build the UK's most compliant cannabis business — with us.

Start a conversation
contact@medicexum.co.uk